The "Mannheim Molecular Intervention Environment (M²OLIE)" Forschungscampus is one of nine currently funded research projects, which as part of the "Forschungscampus - Public-Private Partnership for Innovation" competition received an award from the Ministry of Education and Research on 25 September, 2012. M²OLIE is currently in the middle of the main phase. Successes have been achieved in all of the 16 subprojects.
The aim of M²OLIE is the establishment of a patient-oriented and time-optimised infrastructure for innovative tumour therapies by means of molecular intervention within the framework of a one-stop shop.
In a multidisciplinary development centre with partners from industry, research and public life new methods for molecular imaging, diagnostics and therapeutic intervention of oligometastatic patients in daily clinical practice are developed within the framework of three lead projects. So as to ensure the efficiency of the treatment in a smooth closed-loop process, a process model and a clinical trial management system to establish the organisational processes are set up simultaneously by two cross-sectional projects. This ensures that the entire process from patient registration to diagnosis to final treatment and discharge of the patient(s) can be performed in a limited period of time.
The tight network of medical research, natural sciences, engineering, information science and business administration, and the overcoming of complexity barriers that results, should ensure the success of M²OLIE's concept.
In the intervention area of the future the closed-loop process begins with the application and fusion of various imaging techniques (3-Tesla MRI scanners, PET scanners, SOMATOM Force CT scanners) ( M²IBID lead project ), which supply accurate information for quick navigation of robotic assistance systems (Artis ZEEGO® system and lightweight robots) in the intervention area and the targeted biopsy ( M²INT lead project ). The assistance system transports the samples directly for bioanalysis by means of mass spectrometry, which is followed directly by the radio-chemical production of diagnostics and therapeutics ( M²oBiTE lead project ). These substances are then re-administered in a minimally invasive manner using the robotic assistance system ( M²INT ). All newly-developed methods are integrated into the closed-loop process making optimum use of all human and infrastructural resources ( ProM²OLIE and M²PROCIT cross-sectional projects), so that a time-optimised course of treatment is ensured for each patient from admission to the clinic to discharge following successful treatment.